Huntington’s disease (HD) is caused by Huntingtin (Htt) gene mutation resulting in the loss of striatal GABAergic neurons and motor functional deficits. We report here an in vivo cell conversion technology to reprogram striatal astrocytes into GABAergic neurons in both R6/2 and YAC128 HD mouse models through AAV-mediated ectopic expression of NeuroD1 and Dlx2 transcription factors. We found that the astrocyte-to-neuron (AtN) conversion rate reached 80% in the striatum and >50% of the converted neurons were DARPP32+ medium spiny neurons. The striatal astrocyte-converted neurons showed action potentials and synaptic events, and projected their axons to the targeted globus pallidus and substantia nigra in a time-dependent manner. Behavioral analyses found that NeuroD1 and Dlx2-treated R6/2 mice showed a significant extension of life span and improvement of motor functions. This study demonstrates that in vivo AtN conversion may be a disease-modifying gene therapy to treat HD and other neurodegenerative disorders.
Huntington’s disease (HD) is an autosomal dominant disease characterized by progressive motor, cognitive, and psychiatric symtpoms associated with neuronal dysfunction and atrophy of the striatum and other brain regions1. HD arises due to an expanded chain of polyglutamines in the N terminal region of the huntingtin protein (Htt) leading to intracellular accumulation and aggregation of mutant HTT (mHtt)2,3. The GABAergic medium spiny neurons (MSNs), which represent about 95% of the total neurons within the human striatum4, are susceptible to mHtt aggregates and consequently show early degeneration in the striatum of HD patients5. Many of the symptoms observed in HD patients are highly related to the loss of MSNs in the striatum6 and can be mimicked in rodent7, pig8, and non-human primate9 models. Previous studies have achieved some success in HD animal models through cell transplantation10,11,12 or using antisense oligonucleotides13,14 and CRISPR/Cas9 gene editing technology15 to reduce the mHtt level. Tetrabenazine has been used to treat chorea in HD and other movement disorders but with significant side effects16.
Recent in vivo cell conversion technology provides an alternative approach to regenerate functional new neurons in adult mammalian brains by directly reprogramming local glial cells into neurons17,18,19,20,21,22,23. Using endogenous glial cells for neuroregeneration has emerged as a cell replacement therapy that would avoid transplantation of external cells and therefore minimize potential immunorejection caused by foreign cells24,25,26. Glial cells are the most abundant cell type in adult mammalian brains, constituting over half of the total brain cells. In contrast to non-dividing neurons, glial cells have intrinsic proliferative capability and therefore can serve as source cells for regenerative purpose. In vivo direct reprogramming of adult glial cells into functional neurons has achieved repeated success in both astrocytes and NG2 cells in the mouse brain17,18,19,21,22,27,28 and even monkey brains29. To date, while MSNs have been reprogrammed from fibroblast cells in vitro30, direct in vivo conversion of striatal glial cells into MSNs has not been achieved.
In this study, we discovered that striatal astrocytes can be directly converted into MSNs in the R6/2 mouse model by coexpression of two neural transcription factors, NeuroD1 and Dlx2, through AAV-based gene therapy. Brain slice recordings reveal that the astrocyte-converted neurons can fire repetitive action potentials and display spontaneous synaptic events, indicating that they are electrophysiologically functional and forming synaptic circuits with other neurons. Interestingly, the converted neurons also can project their axon nerve terminals to distant targets such as substantia nigra pars reticulata (SNr) and the external globus pallidus (GP). Most importantly, in vivo regeneration of GABAergic neurons in the striatum reduces the striatum atrophy, and alleviates a series of phenotypic abnormalities including the improvement of motor functions in the R6/2 HD mouse model. Therefore, our studies provide the proof-of-principle that it is possible to regenerate MSNs in the striatum using local glial cells for the treatment of HD.
Targeting striatal astrocytes for in vivo neuronal conversion
Astrocytes are abundant cells that make up ~30% of the cells in the mammalian CNS and essentially surround every single neuron in the brain31, making them an ideal internal source for cell conversion. Our previous study has demonstrated that ectopic expression of a single neural transcription factor, NeuroD1, in cortical astrocytes can convert them into functional neurons18. However, the total number of in vivo converted neurons by retroviruses is limited, because retroviruses can only express target genes in dividing cells. To overcome this disadvantage of retroviruses, we have made recombinant adeno-associated virus (serotype 2/5, rAAV2/5) for in vivo reprogramming. Among different serotypes of rAAV, we chose rAAV2/5 because it has been reported to infect astrocytes preferentially in the mouse brain32.
To track the astrocyte-converted neurons in the mouse brain, we developed a Cre-FLEx (flip-excision) system which includes a vector expressing Cre recombinase under the control of the GFAP promoter (GFAP::Cre) to target astrocytes, and FLEx vectors with an inverted coding sequence of mCherry-P2A-mCherry or NeuroD1-P2A-mCherry or Dlx2-P2A-mCherry (Fig. 1a). The two inserted genes are separated by P2A self-cleavage site and driven by the strong universal synthetic promoter CAG. Because Dlx2 is a transcription factor critical for generating GABAergic neurons33,34,30,35,36, we tested whether Dlx2 in combination with NeuroD1, which mainly generate glutamatergic neurons18, can convert striatal astrocytes into GABAergic neurons.
To test whether Cre recombinase is specifically overexpressed in the astrocytes, we first injected AAV2/5 GFAP::Cre into the normal mouse striatum (2–5 months), a brain region enriched with GABAergic neurons, which shows early degeneration in HD brains. As expected, almost all of the Cre-expressing cells were GFAP-positive cells, a typical marker for astrocytes (99.2 ± 0.6%, n = 6 mice, 7–21 days post viral injection; Fig. 1b). In order to further investigate the specificity of our Cre-FLEx system, we injected AAV2/5 GFAP::Cre together with AAV2/5-CAG::FLEx-mCherry-P2A-mCherry into the normal mouse striatum. The mice were sacrificed at 21–30 days post-injection (dpi) for immunohistological studies. Of the mCherry-positive cells, the majority of them expressed astrocyte-specific markers including S100β (90.0 ± 0.9%), GFAP (86.6 ± 1.9%) and glutamine synthetase (GS, 92.9 ± 1.3%), with very few expressing other glial markers such as Olig2 (1.1 ± 0.3%), NG2 (3.2 ± 1.5%), and Iba1 (not detected, n ≥ 6 mice for each group; Fig. 1c, d). A few mCherry-expressing cells were NeuN-positive (10.5 ± 0.7%, n = 11 mice; Fig. 1c, d), indicating that a small number of striatal neurons were targeted by our AAV2/5 Cre-FLEx system.
NeuroD1 and Dlx2 reprogram striatal astrocytes into GABAergic neurons
We next tested whether our AAV Cre-FLEx system could drive the conversion of astrocytes into neurons in the striatum by injecting AAV2/5 GFAP::Cre together with AAV2/5-CAG::Dlx2-P2A-mCherry and CAG::NeuroD1-P2A-mCherry into adult wild-type (WT) mice (age 2–5 months). At 7 dpi, we found that all the viral infected cells (mCherry+) in the striatum were GFAP+ astrocytes, among which 81.5% of the mCherry+ cells also coexpressed NeuroD1 (ND1) and Dlx2, while only 12.1% of the mCherry+ cells showed neither ND1 nor Dlx2 expression (Fig. 2a, quantified in Fig. 2c). A small percentage (<5%) of the mCherry+ cells expressed only one of the two transcriptional factors (either ND1+ or Dlx2+), but neither of the TFs was detected in NeuN+ neurons at 7 dpi (Fig. 2a and Supplementary Fig. 1a). In contrast, by 30 dpi, we found that most of the ND1 and Dlx2 signals were coexpressed in NeuN+ neurons (72.7%; Fig. 2b, quantified in Fig. 2c, black dots; Supplementary Fig. 1b), with only a small percentage in astrocytes (4.1%, Fig. 2c, gray dots). These results suggest that coexpression of NeuroD1 and Dlx2 can convert striatal astrocytes into neurons (Fig. 2d).
To further investigate the time course of the astrocyte-to-neuron conversion process in the striatum, three more time points of 11, 15, and 21 dpi were analyzed in addition to 7 and 30 dpi (Fig. 2e). We found that a small percentage (17.8%) of mCherry+ cells showed NeuN+ signal after coexpressing NeuroD1 plus Dlx2 (N + D) at 11 dpi, and such neuronal conversion percentage continuously increased to 33.6% at 15 dpi and 74.1% at 21 dpi (Fig. 2e, f). Parallel to this trend, more and more mCherry+ cells colocalized with NeuN, while less and less mCherry+ cells colocalized with GFAP from 7 dpi (83.5% GFAP+) to 30 dpi (14.2% GFAP+) (Fig. 2e, f). Conversely, in the control group infected by AAV2/5 mCherry alone, most of the mCherry+ cells were GFAP+ astrocytes, with very few of the mCherry+ cells co-labeled with NeuN signal across the time points (Fig. 2f, Supplementary Fig. 2). Because NeuroD1 or Dlx2 alone can convert astrocytes into neurons18,21,35, we further compared their individual effects by injecting the mCherry control, NeuroD1, Dlx2, and NeuroD1 plus Dlx2 into WT mouse striatum. We found that expressing either NeuroD1 or Dlx2 alone in striatal astrocytes also resulted in a number of the mCherry+ cells co-labeled with NeuN, but the conversion efficiency and the number of converted neurons were much lower than the NeuroD1 + Dlx2 group (Supplementary Fig. 3a–c). These results suggest that NeuroD1 and Dlx2 together have synergistic effects in converting striatal astrocytes into neurons.
To identify the neuronal subtypes after NeuroD1 + Dlx2 induced astrocyte-to-neuron conversion in the striatum, we performed a series of immunostaining experiments with a variety of GABAergic markers including GAD67 and GABA for GABAergic neurons; DARPP32 for MSNs; and paravalbumin (PV), somatostatin (SST), neuronal peptide Y, and calretinin (CalR) for striatal interneurons. We found that most of the mCherry+ cells (30 dpi) were GAD67+ (83.9%, n = 10 mice) or GABA+ (85.0%, n = 10 mice) GABAergic neurons (Fig. 2g, h). Furthermore, the majority of the converted neurons were DARPP32+ (55.7%, n = 7 mice; Fig. 2g, h), and a small percentage of the converted neurons were PV+ interneurons (9.6%; Fig. 2g, h), with even fewer other subtypes of interneurons (<5%; Fig. 2h, Supplementary Fig. 4). To conclude, Dlx2 together with NeuroD1 can efficiently convert striatal astrocytes into DARPP32+ GABAergic neurons.
After converting striatal astrocytes into neurons, will the neuron to astrocyte ratio be altered? To answer this question, we analyzed the neuron/astrocyte ratio (Supplementary Fig. 5) and neuron/microglia ratio (Supplementary Fig. 6) in the striatum at 30 days post AAV injection. According to our NeuN and S100β immunostaining, the overall neuronal and astrocytic density as well as the neuron/astrocyte ratio was not significantly changed after astrocyte-to-neuron conversion (Supplementary Fig. 5). One potential explanation for this might be due to the fact that astrocytes are proliferative cells and can divide after neuronal conversion. Indeed, we did observe some S100β+ astrocytes at different stages of cell division in the striatum at 30 days post NeuroD1 + Dlx2 treatment (Supplementary Fig. 5b–d). This might explain why astrocytes did not decrease after neuronal conversion. Similarly, with NeuN and Iba1 immunostaining, we also did not find significant changes in neuronal and microglia density nor the neuron/microglia ratio after astrocyte-to-neuron conversion (Supplementary Fig. 6). Thus, neuronal and glial density are not altered after in vivo cell conversion.
To further validate that the converted neurons originated from astrocytes, we employed GFAP::Cre transgenic mice (Cre77.6, Jackson Lab) to trace cell lineage change by injecting either AAV2/5 FLEx-mCherry alone as a control or AAV2/5 FLEx-NeuroD1-mCherry + FLEx-Dlx2-mCherry for conversion (Fig. 3a, b). As expected, control virus FLEx-mCherry expressed in astrocytes specifically in the Cre77.6 transgenic mouse brain (S100β+, 97.4%, n = 9 mice; GFAP+, 94.3%, n = 8 mice; GS+, 97.8%, n = 7 mice), rather than other types of glial cells or neurons (<5%, n = 7 mice for each group; Supplementary Fig. 7a, b). Only <2% of striatal neurons were labeled by mCherry in the control condition (n = 9 mice, 3 mice were sacrificed at 28 dpi and 6 mice were sacrificed at 58 dpi). In contrast, injection of NeuroD1 plus Dlx2 viruses into the striatum of Cre77.6 transgenic mice revealed a transitional conversion process at different time points following viral infection. Specifically, mCherry+ cells in ND1 + Dlx2 group showed astrocyte morphology at 7 dpi, with strong GFAP and S100β signal but no NeuN signal (Fig. 3c, d; left column); by 28 dpi, many mCherry+ cells lost GFAP and S100β signal but remained NeuN-negative (GFAP− & NeuN− or S100β− & NeuN−), suggesting a transitional stage (Fig. 3c, d; middle column). At 56 dpi, the majority of mCherry+ cells became NeuN+, suggesting the completion of the astrocyte-to-neuron conversion process (GFAP− & NeuN+ or S100β− & NeuN+; Fig. 3c, d, right column). Quantification showed most of the mCherry+ cells were astrocytes (GFAP+ & NeuN−: 97.8%, n = 6 mice; S100β+ & NeuN−: 98.1%, n = 6 mice) at the beginning (7 dpi), then a number of the transient cells were observed at 28 dpi (GFAP+ & NeuN−: 46.0%, n = 6 mice; S100β+ & NeuN−: 47.8%, n = 6 mice), and an abundance of mCherry+ neurons were detected at 56 dpi (GFAP− & NeuN+: 59.1%, n = 6 mice; S100β− & NeuN+: 58.2%, n = 6 mice; Fig. 3e, f). Moreover, we also found that most of the ND1 + Dlx2-converted neurons in the striatum of Cre77.6 mice were DARPP32+ MSNs (61.5 ± 2.6%, n = 8 mice; Supplementary Fig. 7c). These results in astrocyte-specific Cre transgenic mice further demonstrate that striatal astrocytes can be reprogrammed into MSNs after ectopic expression of NeuroD1 and Dlx2.
Converting striatal astrocytes into GABAergic neurons in the R6/2 mouse model
After testing successfully the conversion of striatal astrocytes into GABAergic neurons in the WT mice, we next investigated whether this approach can be used to regenerate GABAergic neurons in a mouse model of HD. In this study, we employed the R6/2 transgenic mouse model for HD, which has been well characterized in terms of the pathogenesis process and widely used for developing therapeutic interventions7. To regenerate GABAergic neurons in the striatum of R6/2 mice (both female and male), we injected AAV2/5 NeuroD1 and Dlx2 together in mice at 2 months old when the HD mice started to show neurological phenotypes. One month after viral injection, in the mCherry control group, we observed many infected cells (mCherry+) with astrocyte-like morphology and immunopositive for S100β (Fig. 4a, left panel; and Fig. 4b, top row); while NeuroD1 + Dlx2-infected cells (mCherry+) became immunopositive for NeuN (Fig. 4a, right panel; and Fig. 4b, bottom row). Quantified data showed that in the control group, 86.7% (n = 6 mice) of mCherry+ cells were labeled by S100β, and only 9.2% of cells (n = 6 mice) were labeled by NeuN (Fig. 4c, cyan bar). In contrast, in NeuroD1 + Dlx2-treated mice, 78.6% (n = 7 mice) of viral infected cells were labeled by NeuN while only 15.3% of mCherry+ cells were labeled by S100β (Fig. 4c, green bar). Therefore, these results demonstrate that the striatal astrocytes in the R6/2 mouse brains can be converted into neurons with high efficiency.
Next, we co-stained mCherry with a variety of GABAergic markers to determine what specific subtypes of GABAergic neurons were converted from astrocytes in R6/2 mouse striatum after injecting NeuroD1 + Dlx2 AAV2/5 (38 dpi). We found that the majority of astrocyte-converted neurons were immunopositive for GAD67 (82.4%, n = 8 mice) or GABA (88.7%, n = 8 mice; Fig. 4d–f), suggesting GABAergic neuron identity. Furthermore, 56.6% of the converted cells were DARPP32-positive MSNs (n = 9 mice, Fig. 4e, f). There were also a few astrocyte-converted neurons immunopositive for PV (8.4%, n = 9 mice; Fig. 4e, f), but they were rarely positive for SST, NPY, and CalR (all < 5%; Fig. 4f and Supplementary Fig. 8). These results demonstrate that ectopic expression of NeuroD1 plus Dlx2 in the striatal astrocytes of R6/2 mice can regenerate a significant number of MSNs for therapeutic treatment.
We further investigated whether in vivo astrocyte-to-conversion could change the glial and neuronal density in the striatum of R6/2 mice. We analyzed the cellular density of neurons and astrocytes as well as neuron/astrocyte ratio (Supplementary Fig. 9) and neuron/microglia ratio (Supplementary Fig. 11) in R6/2 mice with or without cell conversion. Similar to the wild-type mouse striatum, we did not find any significant change in the cellular density nor the neuron/glia ratio in the striatum of R6/2 mice after in vivo cell conversion. We also observed a number of dividing astrocytes in the R6/2 mouse striatum after NeuroD1 + Dlx2 treatment (Supplementary Fig. 9b–d), suggesting that the astrocyte-to-neuron conversion may stimulate proliferation of astrocytes. To test this possibility, we compared the Ki67-labeled dividing astrocytes between control and NeuroD1 + Dlx2 group in R6/2 mouse striatum (30 dpi). We found that compared with the control group, the number of Ki67+ astrocytes in NeuroD1 + Dlx2 group was significantly increased by ~15-fold (p < 0.001, unpaired Student’s t-test; Supplementary Fig. 10). These data suggest that in vivo cell conversion facilitates astrocytic proliferation, explaining why astrocytes are never depleted in the converted areas.
Converting striatal astrocytes into GABAergic neurons in the YAC128 mouse model for HD
Since R6/2 mice are a very severe form of HD mouse model that die too soon to mimic the slow progressing disease symptoms in human patients, we further tested the in vivo astrocyte-to-neuron conversion using a more slowly developing HD mouse model YAC128 at an old age of ~15 months (Supplementary Fig. 12). In this study, we injected hGFAP::GFP control virus into the left striatum and hGFAP::NeuroD1 + hGFAP::Dlx2 into the right striatum of the same YAC128 mice (Supplementary Fig. 12a). At 2 months after viral injection, the control GFP-infected cells were mostly GFAP+ astrocytes, whereas the majority of cells infected by NeuroD1 + Dlx2 had lost GFAP signal and half of them became NeuN+ neurons (Supplementary Fig. 12b, c; quantified in Supplementary Fig. 12d). Furthermore, we found that about half of the converted neurons induced by NeuroD1 + Dlx2 were immunopositive for GABA, and 29.8% of the converted neurons were DARPP32+ cells, with only 3.9% of converted neurons being PV+ (Supplementary Fig. 12e, f; n = 3). Together, these results demonstrate that the striatal astrocytes in the very old YAC128 mouse brains (15 months old) can still be converted into GABAergic neurons.
Functional analysis of converted striatal neurons in the R6/2 mouse brain
We then assessed the functional properties of astrocyte-converted neurons induced by NeuroD1-mCherry and Dlx2-mCherry (mCherry-positive; Fig. 5a) in comparison to the native striatal neurons (neighboring non-converted neurons) in acute striatal slices from R6/2 mice (mCherry-negative; Fig. 5a) using whole-cell recordings at 30–32 dpi following AAV infection. Striatal neurons from WT mice were also recorded for comparison (Fig. 5 and Supplementary Fig. 13). We first compared the Na+-K+ currents (Fig. 5b–g) and found that there was no significant difference of Na+ currents between converted and neighboring non-converted neurons in R6/2 mice, but both significantly smaller than that recorded in WT mice (Fig. 5f). For K+ currents, converted neurons showed similar amplitude to the WT neurons, while the non-converted neurons of R6/2 mice showed slightly smaller amplitude (Fig. 5g; n > 15 neurons from 3 mice per group). Next, for action potential firing, we found that 17 out of 18 mCherry+ cells, and 17 native neurons, were able to fire repetitive action potentials when evoked by step current injection (Fig. 5c, a total of 35 cells from 3 mice were recorded). Regarding basic electrical properties such as the cell membrane input resistance, cell membrane capacitance, resting membrane potential (RMP), action potential (AP) threshold, AP amplitude, and AP frequency, we found no significant differences between native and converted neurons in the R6/2 mice (Fig. 5h–m). When compared with the striatal neurons in the WT mice, the converted neurons in the R6/2 mice had higher input resistance, lower cell capacitance, lower resting membrane potential, and lower action potential amplitude (Fig. 5h–m), suggesting that at 1 month after conversion, these newly converted neurons have not fully matured yet.
Different subtypes of GABAergic neurons have distinct AP firing pattern characteristics37. When analyzing the AP firing pattern of the astrocyte-converted neurons, excluding the single mCherry+ cell incapable of firing an AP, most of the converted neurons (72.2%) showed a regular firing frequency (<80 Hz, n = 13) with a long delay to the initial AP spike upon stimulation30,38 (Fig. 5c–r), consistent with a typical MSN firing pattern in the striatum. We also found that 22.2% of converted neurons displayed a fast firing frequency (>80 Hz, n = 4; Fig. 5r), consistent with a typical PV neuron firing pattern. Moreover, we further investigated whether astrocyte-converted neurons could be incorporated in local synaptic circuits by examining spontaneous postsynaptic currents (sPSCs), which represent functional synaptic inputs to the converted neurons. As shown by the representative traces (Fig. 5d, e), both spontaneous excitatory postsynaptic currents (sEPSCs) and spontaneous inhibitory postsynaptic currents (sIPSCs) were detected in all native neurons (n = 9 from 3 mice) and converted neurons (n = 11 from 3 mice). Furthermore, quantitative analyses found no significant differences in the frequency and amplitude of both sEPSCs and sIPSCs among the native neurons and converted neurons in the R6/2 mice (Fig. 5n–q) as well as the striatal neurons in the WT mice (Supplementary Fig. 13c, d). Together, our electrophysiological analyses suggest that striatal astrocytes in the R6/2 mouse brain can be converted into functional GABAergic neurons and integrate into local synaptic circuits.
Axonal projections of the astrocyte-converted neurons
Striatal MSNs send axonal projections to two distinct nuclei within the basal ganglia, the external globus pallidus (GP) and the substantia nigra pars reticulata (SNr). Due to the severe loss of MSNs in the striatum, these two output pathways are severely disrupted in the HD brain6,39. We therefore investigated whether the astrocyte-converted neurons in the striatum could send their axonal projections into these two targets. Indeed, we found a clear mCherry+ axonal tract extending from the striatum to the GP and SNr in NeuroD1 plus Dlx2-treated R6/2 mice (Fig. 6a and Supplementary Fig. 14), but such mCherry+ axonal tract was not detected in the control mCherry alone-injected mice (Supplementary Fig. 15a). Further immunostaining showed that the mCherry+ puncta (axonal nerve terminals) in both the GP and SNr were co-labeled with vGAT, a marker of pre-synaptic GABAergic nerve terminals (Fig. 6b). Quantified data showed that the intensity of the vGAT in the GP and SNr were significantly increased in NeuroD1 plus Dlx2-treated R6/2 mouse brains (Fig. 6c and Supplementary Fig. 15b). These findings demonstrate that the astrocyte-converted neurons can send out GABAergic nerve projections to strengthen GABAergic outputs from the striatum to the GP and SNr in the R6/2 mouse brain.
To further investigate the progress of axonal projections after NeuroD1 + Dlx2 induced in vivo conversion in the R6/2 mouse brain, we injected a retrograde tracer, cholera toxin subunit B (CTB), into the GP or SNr at two different time points, 21 or 30 dpi. At 7 days post CTB injection, the mice were sacrificed for analysis of the CTB-labeled neurons in the striatum (see schematic illustration in Fig. 6d). Sagittal brain sections were made for validating the CTB injected sites (Supplementary Fig. 16). When CTB was injected at 21 dpi, we found a number of CTB-labeled native neurons (NeuN+, mCherry−) in the striatum as expected, but very few of the converted neurons (NeuN+, mCherry+) were labeled by CTB (GP = 8.2%, n = 509 from 5 mice; SNr = 3.5%, n = 483 from 5 mice; Fig. 6e–g). However, when CTB was injected at 30 dpi, we found that CTB was not only detected in native neurons but also in converted neurons (Fig. 6e, f). Quantified data showed that the percentage of CTB-labeled converted neurons was significantly increased when CTB was injected at 30 dpi compared with 21 dpi (GP = 27.7%, n = 535 neurons from 5 mice, p = 0.014; SNr = 29.4%, n = 511 neurons from 5 mice, p = 0.004, unpaired Student’s t-test; Fig. 6g). Therefore, these data demonstrate that the in vivo converted MSNs can extend their axonal projections into the GP and SNr in the R6/2 mouse brain.
Alleviation of neurodegeneration in R6/2 mice by in vivo cell conversion
Huntington’s disease is an autosomal dominant disorder associated with a mutation in the gene encoding huntingtin (Htt). The mutation leads to excessive polyglutamine repeats yielding mutant Htt (mHtt) aggregation and subsequent neurodegeneration, particularly in the striatum. Because the newly generated neurons are converted from astrocytes and mHtt aggregation has been detected both in neurons and astrocytes in R6/2 mouse striatum40, we compared the progress of mHtt inclusions in striatal astrocytes and neurons at age 60 days (P60) and 90 days (P90) in the R6/2 mouse striatum. We found that mHtt nuclear inclusions were detected at P60 in 20.6% of S100β positive astrocytes and 71.1% in neurons (Supplementary Fig. 17a, b). At 3 months old, 35.8% astrocytes and 75.5% of neurons displayed mHtt inclusions (Supplementary Fig. 17a, b). These data suggest that astrocytes have less mHtt inclusions than neurons in the R6/2 mouse striatum. Interestingly, we found that the astrocyte-converted neurons (51.1%, n = 151 neurons from 12 mice) displayed less mHtt inclusions when compared with the native neurons (77.1%, n = 655 neurons from 12 mice; p < 0.002, one-way ANOVA with Bonferroni’s post hoc test), or the neurons in the control group (80.3%, n = 709 neurons from 11 mice; p < 0.001, one-way ANOVA with Bonferroni’s post hoc test) (Fig. 7a,c). These data indicate that in the R6/2 mouse striatum, neurons have more mHtt nuclear inclusions than astrocytes and the astrocyte-converted neurons have less mHtt nuclear inclusions than preexisting neurons.
Striatum atrophy caused by neurodegeneration has been reported previously in the R6/2 mouse brain41. Consistently, we also observed striatal atrophy in R6/2 mice compared with their WT littermates (Supplementary Fig. 17c). Quantification data showed a 31.8% reduction in the striatum volume in 3-month-old R6/2 mice (n = 9 mice, p < 0.001, one-way ANOVA with Bonferroni’s post hoc test; Fig. 7d). Remarkably, we found that the striatum atrophy was alleviated in the NeuroD1 plus Dlx2-treated R6/2 mice compared with the control virus-treated R6/2 mice (Fig. 7b; AAV2/5 were injected at P60, mice were sacrificed at P98). Quantified data showed 30.3% striatum atrophy in the control virus-treated group (n = 6 mice), but only 16.9% striatum atrophy in the NeuroD1 plus Dlx2 group (n = 7 mice, p = 0.004, one-way ANOVA with Bonferroni’s post hoc test; Fig. 7d). Therefore, these results suggest that the in vivo astrocyte-to-neuron conversion therapy can reduce the striatum atrophy in R6/2 mice.
Attenuation of phenotypic deficits in R6/2 mice by in vivo cell conversion
The R6/2 mice display a progressive neurological phenotype that mimics many of the features of HD patients7. We therefore examined whether the in vivo cell conversion approach could alleviate the abnormal phenotypes in the R6/2 mice using a series of behavioral tests. We first performed the catwalk behavioral test to evaluate the gait changes in the R6/2 mice in comparison to their WT littermates (P90–97). We found that the average stride length was significantly reduced in the R6/2 mice when compared with WT littermates (WT = 5.80 ± 0.30 cm, n = 13 mice, 6 male and 7 female; R6/2 = 3.91 ± 0.11 cm, n = 10, 3 male and 7 females; p < 0.001, one-way ANOVA with Bonferroni’s post hoc test; Fig. 8a, b and Supplementary movie 1–2). To test the effect of our gene therapy, R6/2 mice received intracranial AAV2/5 injection bilaterally at P60 and after 30–37 days post viral injection underwent the catwalk behavioral test (Fig. 8k). We found that the stride length was significantly improved in the NeuroD1 plus Dlx2-treated mice (4.91 ± 0.13 cm, n = 19, 8 males and 11 females; p < 0.001, one-way ANOVA with Bonferroni’s post hoc test), compared with the control AAV2/5 mCherry-injected mice (3.95 ± 0.14 cm, n = 13, 6 males and 7 females; Fig. 8a, b and Supplementary movie 3–4). There was no significant difference in footprint width between different groups (Fig. 8a,c). We also assessed the locomotion activity with the open field test. We found that the total travel distance of R6/2 mice (in 20 min) showed a dramatic decrease (1886 ± 252 cm, n = 12, 5 males and 7 females; p < 0.001, one-way ANOVA with Bonferroni’s post hoc test) compared with the WT littermates (6163.8 ± 263.0 cm, n = 14, 7 males and 7 females; Fig. 8d, e). Remarkably, the walking distance showed a significant increase in the NeuroD1 plus Dlx2-treated R6/2 mice (3648 ± 367 cm, n = 18 mice, 10 male and 8 female mice), compared with the mCherry-treated R6/2 mice (2023 ± 331 cm, n = 12 mice, 5 male and 7 female mice; one-way ANOVA with Bonferroni’s post hoc test; Fig. 8d, e). These data suggest that the in vivo cell conversion approach significantly improves the motor functions of the R6/2 mice.
In addition, we also examined the body weight, clasping behavior, and grip strength of the R6/2 mice after gene therapy treatment. R6/2 mice have been reported to lose body weight at 8 weeks old42. To test our gene therapy effects, the R6/2 mice were randomly divided into two groups, and the body weight was measured 7 days before surgery. No significant difference was found between the two groups (p = 0.367; Fig. 8f). Interestingly, the R6/2 mice that were treated with NeuroD1 plus Dlx2 lost less body weight than the R6/2 mice that were injected with the control virus at 30 dpi (Ctrl = 21.13 ± 0.39 g, n = 25, 9 females and 16 males; N + D = 22.42 ± 0.38 g, n = 28, 11 females and 17 males; p = 0.021, unpaired Student’s t-test; Fig. 8f). Next, we used the paw clasp test to measure dystonia and dyskinesia in the R6/2 mice. The typical clasping phenotype (Fig. 8g, top panel) was observed in most of the R6/2 mice. However, the percentage of R6/2 mice showing clasping was significantly reduced after NeuroD1 plus Dlx2 treatment (Ctrl = 88.2%, n = 34, 14 females and 20 males; N + D = 67.7%, n = 31, 13 females and 18 males; p = 0.045, 2-sided Pearson Chi-square test; Fig. 8h). Moreover, the clasping score was also significantly decreased in NeuroD1 plus Dlx2 group (Ctrl = 3.4 ± 0.4, n = 34, 14 females and 20 males; N + D = 2.3 ± 0.4, n = 31, 13 females and 18 males; p = 0.040, unpaired Student’s t-test; Fig. 8i and Supplementary movie 5–6). We further measured the grip strength and found that there was no significant difference between the control virus-treated and the NeuroD1 plus Dlx2-treated R6/2 mice (Fig. 8j). Remarkably, when the survival rate of R6/2 mice was analyzed at 38 dpi (viral injection at 2 months old), 93.9% of the R6/2 mice that were injected with NeuroD1 plus Dlx2 were still alive, but only 55.2% of the R6/2 mice that received control AAV2/5 mCherry injection were alive, which is expected for R6/2 mice at this age (P < 0.001, 2-sided Pearson Chi-square test; Fig. 8l). Altogether, these results demonstrate that in vivo regeneration of GABAergic neurons in the striatum of R6/2 mice can partially rescue the phenotypic deficits and extend the life span.
In this study, we demonstrate that striatal astrocytes in the R6/2 and YAC128 mouse models for HD can be converted into GABAergic neurons and alleviate motor functional deficits. The in vivo converted neurons show similar electrophysiological properties to their neighboring preexisting neurons, and send long-range axonal projections to the GP and SNr in a time-dependent manner. Our NeuroD1 and Dlx2-based gene therapy partially rescued motor functional deficits and increased the survival of R6/2 mice. This proof-of-principle study illustrates a neuroregenerative gene therapy to treat neurodegenerative disorders through in vivo astrocyte-to-neuron conversion approach.
This work demonstrated the in vivo regeneration of GABAergic neurons, and in particular the DARPP32+ neurons with similar electrophysiological properties to the preexisting neurons. An immediate concern was whether these newly converted neurons were actually preexisting neurons, because AAV itself can infect both astrocytes and neurons. This has been carefully considered but found incompatible with the results we observed. First, consistent with the use of GFAP::Cre to restrict viral expression in astrocytes, we found that essentially all the NeuroD1 + Dlx2-infected cells were indeed GFAP+ astrocytes at early time points (before 7 dpi). These viral infected astrocytes gradually lost GFAP signal while acquired NeuN signal, showing a clear time-dependent transition from astrocytic population to neuronal population. If it is not because of AtN conversion, it is impossible to explain such gradual transition from astrocytes to neurons. Second, our axonal projection experiments also showed a time-dependent retrograde labeling of the newly converted neurons, consistent with gradual maturation and axonal projections from newly generated neurons instead of preexisting neurons. The control AAV mCherry group did not show such time-dependent axonal projections, consistent with the fact that no new neurons were converted in the control group. Together, these results suggest that there is no alternative explanation that can account for the gradual transition from astrocytic population to neuronal population other than direct AtN conversion.
Previous studies have reported that transplanting external cells might generate new neurons in animal models for HD43. For example, transplantation of hESC-derived DARPP32+ GABAergic neurons or human NSCs may improved motor functions10,44. Besides stem cells, human fibroblast cells may be converted into striatal GABAergic neurons using microRNAs (miR-9/9* and miR-124) combined with transcription factors (Ctip2, Dlx1, Dlx2, and Myt1L) before transplanted into the mouse brain30. On the other hand, cell transplantation also faces a significant challenge such as long-term survival in a completely different environment from that before transplantation45. Besides generating new neurons, whether right neurons are generated in the right place and then project to the right targets to form right circuits is even more critical for brain repair. In comparison to transplantation of external cells, the astrocyte-converted neurons are in the right place from the very beginning. Therefore, the in situ astrocyte-converted neurons may integrate into the local environment much more easily than externally transplanted cells. It is now also possible to generate a variety of subtypes of neurons with the right combination of transcription factors46,47,48. We demonstrate in this study that combining NeuroD1 and Dlx2 together can generate DARPP32+ neurons in the striatum. The importance of Dlx2 in generating GABAergic neurons has been reported before33,34,36, such as the direct conversion of human fibroblast cells into striatal neurons using microRNAs plus transcription factors Dlx1 and Dlx230. Moreover, because astrocytes are widely distributed throughout the CNS and have intrinsic proliferation capability, our in vivo cell conversion technology may offer an economical way to regenerate a large number of new neurons for the treatment of neurodegenerative disorders such as HD.
Like any new technology, there are of course limitations of the emerging in vivo cell conversion technology. One obvious limitation is that there must be glial cells present for conversion. When injury or degeneration is so severe that a cavity has formed, or when glial cells themselves are significantly damaged, there will be a deficit of glial source to enact the conversion. In such severe injury condition, it may be necessary to transplant external cells to fill the cavity first for tissue repair49. Another limitation is for the treatment of diseases caused by gene mutations, such as the Htt mutation in R6/2 mouse model for HD used in this study. Converting astrocytes into neurons does not directly address the gene mutation problem. The converted neurons sooner or later may develop the mHtt inclusions and degenerate again. One possible solution is to combine the cell conversion approach together with CRISPR gene editing techniques to correct the gene mutation15 so that the converted neurons may survive better.
In conclusion, this study demonstrates not only at the cellular level of regenerating GABAergic neurons but also at the functional level of circuit reconstruction and motor behavioral improvement. The significant extension of life span in the R6/2 HD mouse model after our NeuroD1 + Dlx2 gene therapy treatment suggests that a potential disease-modifying therapy is now on the horizon for HD and other neurodegenerative disorders.
Animals were housed in a 12:12 h light:dark cycle with free access to chow and water. The R6/2 strain (B6CBA-Tg(HDexon1)62Gpb/3J) was maintained by ovarian transplant hemizygote females × B6CBAF1/J males, both were purchased from Jackson Laboratory. Mice were genotyped by PCR after weaning (P21–27) and the littermates without mutation were used as normal mice (2–5 months). Some of the R6/2 transgenic mice were directly purchased from the Jackson Laboratory at ages of 4–6 weeks. The GFAP::Cre transgenic mice (B6.Cg-Tg(Gfap-cre)77.6Mvs/2J, Cre77.6) were purchased from Jackson Laboratory as well. The 2–5-month-old hemizygous mice were used for AAV injection. Both male and female mice were used in this study. Experimental protocols were approved by the Pennsylvania State University IACUC and in accordance with guidelines of National Institutes of Health.
YAC128 transgenic mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (NBRI). The mice were housed in a 12 h light/dark cycle and supplied with enough food and water. Experimental protocols were approved by Jinan University IACUC.
Recombinant AAV2/5 was produced in 293 AAV cells (Cell Biolabs). Briefly, polyethylenimine (PEI, linear, MW 25,000) was used for transfection of triple plasmids: the pAAV expression vector, pAAV5-RC (Cell Biolab) and pHelper (Cell Biolab). At 72 h post transfection, cells were harvested and centrifuged. The cells were then cyclically frozen and thawed four times by placing it on dry ice/ethanol and a 37 °C water bath. AAV crude lysate was purified by centrifugation at 54,000 rpm for 1 h in discontinuous iodixanol gradients with a Beckman SW55Ti rotor. The virus-containing layer was extracted and concentrated by Millipore Amicon Ultra Centrifugal Filters. The AAV2/5 genome copies (GC) per injection for GFAP::Cre is 3.55 × 107 GC; CAG::FLEx-mCherry-P2A-mCherry is 2.54 × 109 GC; CAG::FLEx-NeuroD1-P2A-mCherry is 1.59 × 109 GC and CAG::FLEx-Dlx2-P2A-mCherry is 2.42 × 109 GC. Virus titer was 7.7 × 1010 GC/ml for GFAP::Cre; 1.65 × 1012 GC/ml for FLEx-mCherry-P2A-mCherry; 2.07 × 1012 GC/ml for FLEx-NeuroD1-P2A-mCherry and 3.14 × 1012 GC/ml for FLEx-Dlx2-P2A-mCherry, determined by QuickTiter™ AAV Quantitation Kit (Cell Biolabs).
For AAV injection in YAC128 mice, human GFAP promoter was used to drive GFP and NeuroD1 or Dlx2 expression. hGFAP::GFP and hGFAP::NeuroD1-P2A-GFP were packaged with capsids of serotype 9. hGFAP::Dlx2-P2A-GFP was packaged with capsids of serotype 5. Virus stocks were adjusted to 2–3 × 1012 GC/mL in 0.001% F-68.
Stereotaxic viral injection
Brain surgeries were conducted on 2–5-month-old wild-type mice or 2-month-old R6/2 mice for AAV injection. The mice were anesthetized by injecting ketamine/xylazine (120 mg/kg and 16 mg/kg) into the peritoneum, followed by fur trimming, and placement into a stereotaxic setup. Artificial eye ointment was applied to cover the eye for protection purposes. Oxygen was provided for the R6/2 mice throughout surgery. The operation began with a midline scalp incision followed by the creation of a (~1 mm) drill hole on the skull for intracranial injection into the striatum (AP +0.6 mm, ML ±1.8 mm, DV −3.5 mm). Each mouse received a bilateral injection of AAV2/5 using a 5 μl syringe and a 34 G needle. The injection volume was 2 μl and the flow rate was controlled at 0.2 μl/min. Some R6/2 mice received secondary surgery after AAV2/5 injection where CTB (ThermoFisher, C34775) was delivered. The mice were anesthetized by 2.5% Avertin (250–325 mg/kg) and oxygen was supplied during the surgery. CTB (0.5 μg/site) was injected into the globus pallidus (AP −0.2 mm, ML 1.8 mm, DV −4.0 mm) or substantia nigra pars reticulata (AP −3.0 mm, ML 1.7 mm, DV −4.0 mm), two target areas of the striatal MSN’s projections. After viral injection, the needle was kept in place for at least 10 min before being slowly withdrawn. Coordinates are measured from bregma.
For viral injection in YAC128 mice, 15-month-old YAC128 mice were used for experiments because of its slow disease progression. The mice were anesthetized with 20 mg/kg 2.5% Avertin (a mixture of 25 mg/ml of Tribromeothylethanol and 25 μg/ml T-amylalcohol) through intraperitoneal injection and then placed in the stereotaxic frame. Viruses were injected into the striatum (coordinate of AP: +1.0 mm, ML: ±2.0 mm, DV: −3.0 mm), with one side injecting control AAV (hGFAP::GFP) and the other side injected with NeuroD1 + Dlx2. The injection volume and flow rate were controlled as 3 μl at 0.2 μl/min. After injection, the injection pipette was kept in place for about 10 min and then slowly withdrawn.
Immunohistochemistry and analysis
For brain slice immunostaining, the animals were deeply anesthetized with 2.5% Avertin and then quickly perfused with ice-cold artificial cerebrospinal fluid (aCSF) to wash away the blood. Then brains were quickly removed and post-fixed in 4% PFA overnight at 4 °C in darkness. After fixation, the samples were cut into 40-μm sections by a vibratome (Leica, VTS1000). Brain slices were washed three times in phosphate buffer solution (PBS, pH: 7.35, OSM: 300) for 10 min each. Blocking was performed for 2 h in 0.3% triton PBS + 5% normal donkey serum (NDS). Primary antibody was diluted in 0.05% triton PBS + 5% NDS and incubated in a moist environment at 4 °C for two nights (see Table 1 for the primary antibody information). After washing three times in PBS, the samples were incubated with appropriate secondary antibodies conjugated to Alexa Flour 405, or Alexa Flour 488, or Cy3, or Alexa Flour 647 (1:500, Jackson ImmunoResearch) for 2 h at room temperature, followed by extensive washing in PBS. The secondary antibody was diluted in 0.05% triton PBS + 5% NDS. For GAD67 and GABA immunostaining, the samples were fixed in 4% PFA and 0.2% glutaraldehyde, the sections were mildly permeabilized in 0.05% Triton PBS for 30 min, and Triton was removed for rest of the immunostaining procedure. The samples were mounted on glass slides and stored at 4 °C in darkness.
The images were acquired by a Zeiss confocal microscope (LSM 800). For quantification, 2–6 regions in the striatum were randomly selected for confocal imaging (×20 lens 2–4 regions; ×40 lens 4–6 regions). Most imaging analysis was performed with Zeiss software ZEN. In order to avoid the impact of human bias on the analysis, some of the mouse information was blinded during confocal imaging. Moreover, image analysis was further performed blindly: the person who did the quantification did not know the injected virus information. After quantification, another person decoded the mouse information. The Image J software was used for quantifying the intensity of vGAT.
Brain slices were prepared at 30–32 days after AAV injection, and cut to 300-μm-thick coronal sections with a vibratome (Leica, VTS1200) at room temperature in cutting solution (in mM: 93 NMDG, 93 HCl, 2.5 KCl, 1.25 NaH2PO4, 30 NaHCO3, 20 HEPES, 15 glucose, 12 N-Acetyl-L-cysteine, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 7 MgSO4, 0.5 CaCl2, pH 7.3–7.4, 300 mOsmo, solution was bubbled with 95% O2/5% CO2). Then, slices were transferred to holding solutions with continuous 95% O2/5% CO2 bubbling (in mM): 92 NaCl, 2.5 KCl, 1.25 NaH2PO4, 30 NaHCO3, 20 HEPES, 15 glucose, 12 N-Acetyl-L-cysteine, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 2 MgSO4, 2 CaCl2. After 0.5–1 h recovery, the slices were transferred to a chamber for electrophysiology study. The recording chamber was filled with artificial cerebral spinal fluid (ACSF) containing: 119 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4, 2.5 mM CaCl2, 1.3 mM MgCl2 and 10 mM glucose, and constantly bubbled with 95% O2 and 5% CO2 at 32–33 °C. Whole-cell recordings were conducted using a pipette solution consisting of 135 mM K-Gluconate, 5 mM Naphosphocreatine, 10 mM KCl, 2 mM EGTA, 10 mM HEPES, 4 mM MgATP, and 0.5 mM Na2GTP (pH 7.3, adjusted with KOH, 290 mOsm/L). To record the spontaneous synaptic events, the potassium gluconate in the pipette solution was replaced with Cs-methanesulfonate to block K+ channels and reduce noise. Pipette resistance was typically 4–6 MΩ, and series resistance was around 20–40 MΩ. The membrane potential was held at −70 mV for sEPSC recording, and at 0 mV for sIPSC recording50. Data were collected using pClamp 9 software (Molecular Devices, Palo Alto, CA), sampled at 10 kHz, and filtered at 1 kHz, then analyzed with pClamp 9 Clampfit and MiniAnalysis software (Synaptosoft, Decator, GA).
Nissl staining and quantification of relative striatum volume
To assess striatal atrophy, brains were sliced and collected in a serial manner allowing accurate identification of the anterior/posterior sections relative to the bregma so that the striatal volume could be calculated. Every 5th section (anterior and posterior of bregma) covering the entire striatum was included for calculating the striatum volume. Samples were mounted on glass slides and allowed to dry at room temperature for 24 h and then stained with crystal violet. The stained sections were photographed by Keyence microscope (BZ9000). Striatum area was outlined according to the mouse brain atlas and the size of the striatum was blindly measured by Image J software. Striatal volume was calculated using Cavalieri’s principle41 (volume = s1d1 + s2d2 + … + sndns, s is surface area and d is the distance between two sections). All of the values were normalized to the striatal volume in wild-type littermates.
Behavioral tests and analyses
The mice were acclimated to the behavioral testing room for 1 h in order to reduce the effect of the stress associated with movement of the cages. Both female and male mice were included for behavioral tests, and the female and male mouse number was stated in the results section.
Catwalk. The CatWalk XT 10.6 (Noldus) system was used to analyze gait deficits in R6/2 mice. The stride length and footprint width were analyzed to evaluate the treatment effects of in vivo cell conversion. The maximum run duration was 6 s, with a maximum speed variation of 60% in order to reduce variability in the mouse’s natural gait pattern. Three compliant trials were acquired per mouse in order to ensure reproducibility. Before each trial the walkway was cleaned with 70% ethanol and dried, then fanned in order to reduce any remaining alcohol odor. During the trial period the room light was turned off. The mouse gait was analyzed automatically by the system software (CatWalk XT 10.6, Noldus). To avoid detections of false footprint, such as mouse excrement, nose-point, tail, and belly, the analysis results were further checked visually and corrected blindly.
Open field test. The open field test was used to assess the locomotion activity in the R6/2 mice. The study arena was a white open-top box (50 × 50 × 30 cm3), and the mouse was gently placed in the center to start the test. The computer program (EthoVision XT Version 8, Noldus) was calibrated to the arena and set to track center-point, nose-point, and tail-point of the mouse using dynamic subtraction. The mouse freely moved in the open box for 20 min, and its route was automatically tracked and analyzed by the software (Ethovision XT Version 8).
Clasping. The clasping test was used to measure dystonia and dyskinesia3. The mouse was suspended upside down by its tail for 14 s. The 14-s trial was split into seven intervals, with 2-s for each interval. The animal was awarded a score of 0 (no clasping) or 1 (clasping). The score for the seven intervals was summed for each mouse allowing a maximum score of 7. Clasping was defined as a behavior whereby paws crossed and came to the chest for any period of time within each 2-s interval51. The test was video recorded and analyzed later in a blind fashion.
Mouse weight. The mouse weight was tracked in order to observe any severe weight loss, as the R6/2 mouse model is known to have up to 20% weight decrease after 3 months of age. The mice were weighed individually each Tuesday at 5:00 PM in the animals’ homeroom inside an approved vent hood.
Grip strength. The grip strength test was used to quantitatively measure the strength of the mouse forepaws. The grip strength meter (BIO-GS3, Bioseb) was set to record in grams. Each mouse was held by its tail and allowed to grasp the metal grid with only its two front paws. The mouse was pulled until failure to record the maximum strength for each trial. Each mouse was tested three times per time point and the three trials were then averaged to calculate the mean grip strength for each time point tested.
Data were shown as mean ± standard error of mean (SEM) or mean ± standard deviation (SD), or box plot. Two-tailed Student’s t-test (paired or unpaired) was performed to determine the statistical significance between two-group comparison, and the Chi-square test was used to compare the difference of percentage between two groups. One-way ANOVA analysis (GraphPad Prism 7.0) followed by Bonferroni post hoc test was used to for multiple group comparisons. P < 0.05 was considered statistically significant.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The data that support the findings of this study are available from the corresponding author upon reasonable request. The source data underlying Figs. 1d, 2c–h, 3e, f, 4c–f, 5f–q, 6c–g, 7c, d, 8b, c, 8e–l, and Supplementary Figs. 3b, c, 5e–g, 6b–d, 7b, 9e–g, 10c, 11b–d, 12d–f, 17b are provided as a Source Data file.
Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 15005 (2015).
Macdonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons-disease chromosomes. Cell 72, 971–983 (1993).
Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506 (1996).
Reinius, B. et al. Conditional targeting of medium spiny neurons in the striatal matrix. Front Behav. Neurosci. 9, 71 (2015).
Rikani, A. A. et al. The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann. Neurosci. 21, 112–114 (2014).
Rangel-Barajas, C. & Rebec, G. V. Dysregulation of corticostriatal connectivity in Huntington’s disease: a role for dopamine modulation. J. Huntingt. Dis. 5, 303–331 (2016).
Pouladi, M. A., Morton, A. J. & Hayden, M. R. Choosing an animal model for the study of Huntington’s disease. Nat. Rev. Neurosci. 14, 708–721 (2013).
Yan, S. et al. A huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington’s disease. Cell 173, 989–1002 (2018).
Yang, S. H. et al. Towards a transgenic model of Huntington’s disease in a non-human primate. Nature 453, 921–924 (2008).
Ma, L. et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 10, 455–464 (2012).
Wu, M. et al. A chemical recipe for generation of clinical-grade striatal neurons from hESCs. Stem Cell Rep. 11, 635–650 (2018).
Sassone, J., Papadimitriou, E. & Thomaidou, D. Regenerative approaches in Huntington’s disease: from mechanistic insights to therapeutic protocols. Front. Neurosci. 12, 800 (2018).
Miniarikova, J. et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 24, 630–639 (2017).
Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74, 1031–1044 (2012).
Yang, S. et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J. Clin. Investig. 127, 2719–2724 (2017).
Claassen, D. O. et al. Tetrabenazine treatment patterns and outcomes for chorea associated with Huntington disease: a retrospective chart review. J. Huntingt. Dis. 7, 345–353 (2018).
Torper, O. et al. In vivo reprogramming of striatal NG2 glia into functional neurons that integrate into local host circuitry. Cell Rep. 12, 474–481 (2015).
Guo, Z. Y. et al. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell 14, 188–202 (2014).
Rivetti di Val Cervo, P. et al. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat. Biotechnol. 35, 444–452 (2017).
Niu, W. et al. In vivo reprogramming of astrocytes to neuroblasts in the adult brain. Nat. Cell Biol. 15, 1164–1175 (2013).
Brulet, R. et al. NEUROD1 instructs neuronal conversion in non-reactive astrocytes. Stem Cell Rep. 8, 1506–1515 (2017).
Liu, Y. G. et al. Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo. J. Neurosci. 35, 9336–9355 (2015).
Torper, O. et al. Generation of induced neurons via direct conversion in vivo. Proc. Natl Acad. Sci. USA 110, 7038–7043 (2013).
Li, H. D. & Chen, G. In vivo reprogramming for CNS repair: regenerating neurons from endogenous glial cells. Neuron 91, 728–738 (2016).
Barker, R. A., Gotz, M. & Parmar, M. New approaches for brain repair-from rescue to reprogramming. Nature 557, 329–334 (2018).
Srivastava, D. & DeWitt, N. In vivo cellular reprogramming: the next generation. Cell 166, 1386–1396 (2016).
Pereira, M. et al. Direct reprogramming of resident NG2 glia into neurons with properties of fast-spiking parvalbumin-containing interneurons. Stem Cell Rep. 9, 742–751 (2017).
Niu, W. Z. et al. SOX2 reprograms resident astrocytes into neural progenitors in the adult brain. Stem Cell Rep. 4, 780–794 (2015).
Long-Jiao Ge, F.-H.Y. et al. In vivo neuroregeneration to treat ischemic stroke in adult non-human primate brains through NeuroD1 AAV-based gene therapy. bioRxiv https://doi.org/10.1101/816066 (2019).
Victor, M. B. et al. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron 84, 311–323 (2014).
Liddelow, S. A. & Barres, B. A. Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957–967 (2017).
Ortinski, P. I. et al. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat. Neurosci. 13, 584–591 (2010).
McKinsey, G. L. et al. Dlx1&2-dependent expression of Zfhx1b (Sip1, Zeb2) regulates the fate switch between cortical and striatal interneurons. Neuron 77, 83–98 (2013).
Pla, R. et al. Dlx1 and Dlx2 promote interneuron GABA synthesis, synaptogenesis, and dendritogenesis. Cereb. Cortex 28, 3797–3815 (2018).
Heinrich, C. et al. Directing astroglia from the cerebral cortex into subtype specific functional neurons. Plos Biol. 8, e1000373 (2010).
Yang, N. et al. Generation of pure GABAergic neurons by transcription factor programming. Nat. Methods 14, 621–628 (2017).
Gentet, L. J. Functional diversity of supragranular GABAergic neurons in the barrel cortex. Front Neural Circuits 6, 52 (2012).
Kreitzer, A. C. Physiology and pharmacology of striatal neurons. Annu Rev. Neurosci. 32, 127–147 (2009).
Barry, J., Akopian, G., Cepeda, C. & Levine, M. S. Striatal direct and indirect pathway output structures are differentially altered in mouse models of Huntington’s disease. J. Neurosci. 38, 4678–4694 (2018).
Tong, X. et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington’s disease model mice. Nat. Neurosci. 17, 694–703 (2014).
Paul, B. D. et al. Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington’s disease. Nature 509, 96–100 (2014).
Menalled, L. et al. Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Neurobiol. Dis. 35, 319–336 (2009).
Holley, S. M. et al. Therapeutic effects of stem cells in rodent models of Huntington’s disease: Review and electrophysiological findings. CNS Neurosci. Ther. 24, 329–342 (2018).
Reidling, J. C. et al. Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington’s disease mice. Stem Cell Rep. 10, 58–72 (2018).
Goldman, S. A. Stem and progenitor cell-based therapy of the central nervous system: hopes, hype, and wishful thinking. Cell Stem Cell 18, 174–188 (2016).
Tsunemoto, R. et al. Diverse reprogramming codes for neuronal identity. Nature 557, 375–380 (2018).
Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035–1041 (2010).
Yang, N., Ng, Y. H., Pang, Z. P., Sudhof, T. C. & Wernig, M. Induced neuronal cells: how to make and define a neuron. Cell Stem Cell 9, 517–525 (2011).
Adil, M. M. et al. hPSC-derived striatal cells generated using a scalable 3D hydrogel promote recovery in a Huntington disease mouse model. Stem Cell Rep. 10, 1481–1491 (2018).
Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708–721 (2012).
Jiang, L. N. et al. Motor and behavioral phenotype in conditional mutants with targeted ablation of cortical D1 dopamine receptor-expressing cells. Neurobiol. Dis. 76, 137–158 (2015).
This work was supported by NIH grant (AG045656) and Charles H. “Skip” Smith Endowment Fund at Pennsylvania State University to G.C. We thank Yuting Bai for mouse weaning and Mei Jiang for mouse genotyping. We would like to thank all Chen Lab members for scientific discussions throughout the progress of this project.
Gong Chen is a co-founder of NeuExcell Therapeutics Inc.
Peer review information Nature Communications thanks Stephan von Hörsten and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wu, Z., Parry, M., Hou, XY. et al. Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington’s disease. Nat Commun 11, 1105 (2020). https://doi.org/10.1038/s41467-020-14855-3
Current Neurology and Neuroscience Reports (2021)
Neuroscience Bulletin (2021)
Compensation for Neurodegeneration by Hippocampal Neurogenesis in Alzheimer’s Disease: Where is the Way?
Neuroscience Bulletin (2021)